AIM
CARM

Acrospire Investment Management’s Carisma Therapeutics CARM Stock Holding History

Acrospire Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-307
Closed -$10K – 232
2017
Q2 		$10K Sell
307
-15
-5% -$500 0.01% 1790
2017
Q1 		$14K Sell
322
-2,349
-88% -$97.9K 0.01% 1763
2016
Q4 		$102K Buy
2,671
+1,716
+180% +$75.6K 0.04% 913
2016
Q3 		$53K Buy
955
+890
+1,369% +$66.3K 0.04% 1019
2016
Q2 		$2K Buy
+65
New +$1.65K ﹤0.01% 1942

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MERSOM
Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's CARM Position: Q3 2017 in Review

Acrospire Investment Management sold out of Carisma Therapeutics (CARM) in Q3 2017, closing a stake of 307 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in CARM in Q2 2016 and held it in 5 quarters. The position peaked at $102K in Q4 2016. 22 funds tracked by Wall St. Rank hold CARM as of Q3 2017.

  • Acrospire Investment Management reported no remaining Carisma Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 307 Carisma Therapeutics shares in Q3 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Carisma Therapeutics in Q2 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Carisma Therapeutics position peaked at $102K in Q4 2016.
  • 22 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.